Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - A population-based study

Acta Oncologica

Volumn 55, Issue 2, 2016, Pages 226-233

  Anuradha, Satyamurthy ^a,b   Donovan, Peter J ^b   Webb, Penelope M ^b   Brand, Alison H ^c   Goh, Jeffrey ^d   Friedlander, Michael ^e   Oehler, Martin K ^f   Quinn, Michael ^g   Steer, Christopher ^h   Jordan, Susan J ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f ROYAL ADELAIDE HOSPITAL   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h Border Medical Oncology Australia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; ANEMIA; ARTICLE; AUSTRALIA; CANCER ADJUVANT THERAPY; CANCER REGISTRY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; NEUTROPENIA; OVARY CARCINOMA; POPULATION RESEARCH; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; COHORT ANALYSIS; MIDDLE AGED; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROCEDURES; PROPORTIONAL HAZARDS MODEL; TIME FACTOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; TIME FACTORS;

EID: 84961365808     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2015.1054950     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Metzger-Filho O, Moulin C, D'Hondt V. First-line systemic treatment of ovarian cancer: A critical review of available evidence and expectations for future directions. Curr Opin Oncol 2010;22:513-20.
3. Jordan S, Steer C, DeFazio A, Quinn M, Obermair A, Friedlander M, et al. Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - a population-based study. Gynecol Oncol 2013;129:310-7.
4. Repetto L, Pace M, Mammoliti S, Bruzzone M, Chiara S, Oliva C, et al. The impact of received dose intensity on the outcome of advanced ovarian cancer. Eur J Cancer 1993;29A:181-4.
5. Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, et al. Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. Gynecol Oncol 2012;124:221-4.
6. Hanna RK, Poniewierski MS, Laskey RA, Lopez MA, Shafer A, Van Le L, et al. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multiagent chemotherapy for epithelial ovarian cancer. Gynecol Oncol 2013;129:74-80.
7. Fauci JM, Whitworth JM, Schneider KE, Subramaniam A, Zhang B, Frederick PJ, et al. Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer. Gynecol Oncol 2011;122:532-5.
8. Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Maggioni A, et al. Relationship between time interval from primary surgery to the start of taxane-plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: Results of a multicenter retrospective Italian study. J Clin Oncol 2005;23:751-8.
9. Flynn PM, Paul J, Cruickshank DJ, Scottish Gynaecological Cancer Trials G. Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer? Gynecol Oncol 2002;86:354-7.
10. Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, et al. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecol Oncol 2013;131:15-20.
11. Wright JD, Herzog TJ, Neugut AI, Burke WM, Lu YS, Lewin SN, et al. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer. Obstet Gynecol 2012;120:871-81.
12. Anuradha S, Webb PM, Blomfield P, Brand AH, Friedlander M, Leung Y, et al. Survival of Australian women with invasive epithelial ovarian cancer: A population-based study. Med J Aust 2014;201:283-8.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83.
14. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, et al. 2004 consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16(Suppl 8):viii7-12.
15. Loibl S, Skacel T, Nekljudova V, Luck HJ, Schwenkglenks M, Brodowicz T, et al. Evaluating the impact of relative total dose intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer - a pooled analysis. BMC Cancer 2011;11:131.
16. Merritt MA, Green AC, Nagle CM, Webb PM. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008;122:170-6.
17. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-8.
18. Lyman GH, Dale DC, Tomita D, Whittaker S, Crawford J. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. Breast Cancer Res Treat 2013;139:863-72.
19. Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: A systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2013;24:2475-84.
20. Aziz MT, Good BL, Lowe DK. Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy. Ann Pharmacother 2014;48:626-32.
21. Cividalli A, Creton G, Ceciarelli F, Strigari L, Tirindelli Danesi D, Benassi M. Influence of time interval between surgery and radiotherapy on tumor regrowth. J Exp Clin Canc Res 2005;24:109-16.
22. Larsen E, Blaakaer J. Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance? Acta Obstet Gynecol Scand 2009;88:373-7.
23. Mahner S, Eulenburg C, Staehle A, Wegscheider K, Reuss A, Pujade-Lauraine E, et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials. Eur J Cancer 2013;49:142-9.
24. Lydiksen L, Jensen-Fangel S, Blaakaer J. Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer? Gynecol Oncol 2014;133:454-9.
25. National Comprehensive Cancer Network Guidelines - Ovarian Cancer Version 3.2012. [cited 2014 Oct 10]. Available from: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.